Thromboembolic diseases such as myocardial infarction, stroke, deep vein thrombosis, the disease has become one of the highest mortality or morbidity worldwide. With the growing aging population, the thrombotic diseases patients are increasing year by year, seriously affecting people's health. At moment treat for thrombotic diseases in clinical drugs included antiplatelet drugs and anticoagulants drugs. According to relevant statistics show that anticoagulants drugs accounted the largest market share of antithrombotic. FXa is pathway of the intersection of endogenous and exogenous coagulation which can be cleaved prothrombin to generate thrombin. By FXa Inhibitor can inhibit the generation of thrombin thereby inhibiting coagulation of blood coagulation and thrombosis. Since FXa Inhibitors have significant advantages,  it becomes a hot research in recent years. Compared with thrombin inhibitor (heparin, low molecular weight heparin, hirudin, etc.) compared Fxa Inhibitor has the following advantages:
1. FXa inhibitor less  quantity use, strong efficacy.
2. To prevent thrombus formation, more safer than other antithrombotic agents. Currently the developing of most international FXa inhibitors   is in the experimental or clinical research phase, only one compound with five carbon sugar structure is approved for marketing. With the growing aging population, the incidence of thromboembolic disease is continuously rising, antithrombotic drugs market will continously  expand. Early developing and marketing of new FXa inhibitors will have a huge potential market.

Conbottpharm could give you: 
1. Best quality in your requirement 
2. Competitive price in China market 
3. Mature Technical support 
4. Professional logistic support 
All we want is win-win business. Send yr. inquiries, you will get it!